TRPV4 Lentiviral Activation Particles (h): sc-401432-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- TRPV4 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- TRPV4 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by TRPV4 Lentiviral Activation Plasmid (h) and TRPV4 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the TRPV4 promoter. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRPV4 Lentiviral Activation Particles (h) | sc-401432-LAC | 200 µl | $455.00 |
TRPV4 encodes a polymodal, Ca2+-permeable TRP channel that functions as a mechanosensor and osmosensor at the plasma membrane, coupling physical and chemical stimuli to intracellular calcium signaling. Channel activation regulates membrane potential and Ca2+-dependent pathways controlling cytoskeletal remodeling, cell volume regulation, and transcriptional responses, including MAPK and CaMK-dependent signaling cascades. TRPV4 activity influences endothelial permeability, nociceptive and inflammatory signaling, and mechanotransduction in cartilage and bone, linking it to processes relevant to edema, pain sensitization, and skeletal homeostasis. Genetic and functional perturbation of TRPV4 has been associated with a spectrum of neuropathic and skeletal dysplasia phenotypes, making it a useful target for studying stimulus-evoked Ca2+ dynamics and downstream gene programs.
TRPV4 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient TRPV4 upregulation across a broader range of human cell types.
TRPV4 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the TRPV4 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous TRPV4 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native TRPV4 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.